GLP-1 medications, specifically semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), work in part by acting on receptors in the brain that regulate hunger
Key Research Areas for 5-Amino-1MQ NNMT enzyme inhibition assays IC50 characterisation, selectivity profiling, and 1-MNA production quantification NAD+ salvage pathway studies nicotinamide flux, NMN and NAD+ pool modulation in vitro SAM/SAH methyl-donor pathway research epigenetic methylation capacity and histone modification studies Adipocyte biology lipogenesis suppression, adipocyte size, white adipose mass, and lipid storage pathway studies SIRT1 and SIRT3 activation and downstream pathway research insulin sensitivity, gluconeogenesis, mitochondrial function Skeletal muscle function and sarcopenia pathway research muscle strength, endurance, and mitophagy-related studies in aged models Gut microbiome modulation research in diet-induced obesity models Cancer cell biology NNMT-overexpressing cell line studies, anti-proliferative pathway investigations Cardiovascular metabolic pathway research homocysteine, SIRT activity, NF-B and STAT3 inflammatory signalling Comparative NNMT inhibitor studies 5-Amino-1MQ vs
SHIRLEY, NY 11967
Must be handled by qualified research personnel in compliance with applicable laws and regulations
The effects of growth hormone on adipose tissue: old observations, new mechanisms
